Related Experiment Video
Updated: Nov 26, 2025

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization
Published on: December 23, 2020
Coronavirus Disease 2019: Virology and Drug Targets
Praveen Thaggikuppe Krishnamurthy1
1Department of Pharmacology, JSS College of Pharmacy, (A constituent College of JSS Academy of Higher Education & Research), Ooty, Tamilnadu,India.
Abstract:
The Coronavirus Disease 2019, a pandemic caused by novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is seriously affecting global health and the economy. As the vaccine development takes time, the current research is focused on repurposing FDA approved drugs against the viral target proteins. This review discusses the current understanding of SARSCoV- 2 virology, its target structural proteins (S-glycoprotein), non-structural proteins (3-chymotrypsin- like protease, papain-like protease, RNA-dependent RNA polymerase, and helicase) and accessory proteins, drug discovery strategies (drug repurposing, artificial intelligence, and high- -throughput screening), and the current status of antiviral drug development.
Insights
This review explores Coronavirus Disease 2019 (COVID-19) virology and drug repurposing strategies. It details SARS-CoV-2 proteins and current antiviral drug development, focusing on FDA-approved medications.
Area of Science:
- Virology
- Drug Discovery
- Infectious Diseases
Background:
- The Coronavirus Disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2, poses significant global health and economic challenges.
- Vaccine development is ongoing, but immediate therapeutic strategies are crucial.
Purpose of the Study:
- To review the current understanding of SARS-CoV-2 virology, including its structural, non-structural, and accessory proteins.
- To discuss various drug discovery strategies, with a focus on repurposing FDA-approved drugs.
- To summarize the current status of antiviral drug development for COVID-19.
Main Methods:
- Literature review of SARS-CoV-2 virology.
- Analysis of drug repurposing, artificial intelligence, and high-throughput screening methodologies.
- Examination of current antiviral drug development pipelines.
Main Results:
- Detailed overview of key SARS-CoV-2 target proteins: S-glycoprotein, 3-chymotrypsin-like protease, papain-like protease, RNA-dependent RNA polymerase, and helicase.
- Exploration of drug repurposing as a viable strategy for rapid therapeutic development.
- Summary of promising antiviral candidates and their developmental stages.
Conclusions:
- Drug repurposing offers a promising avenue for accelerating the availability of COVID-19 treatments.
- Continued research into SARS-CoV-2 targets and drug discovery methods is essential.
- Understanding viral mechanisms is key to developing effective antiviral therapies.
More Related Videos
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Viruses with RNA Genomes
Drug Discovery: Overview
Single Nucleotide Polymorphisms-SNPs
Subviral Agents

